These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 326043)

  • 41. Criticism of pharmacokinetic clearance concepts.
    Keller F; Schoole J
    Int J Clin Pharmacol Ther Toxicol; 1983 Nov; 21(11):563-8. PubMed ID: 6654532
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Editorial: Drug metabolism in disease.
    Lancet; 1974 Apr; 1(7861):790-1. PubMed ID: 4132718
    [No Abstract]   [Full Text] [Related]  

  • 43. Drug metabolism in liver disease.
    Prescott LF; Forrest JA; Adjepon-Yamoah KK; Finlayson ND
    J Clin Pathol Suppl (R Coll Pathol); 1975; 9():62-5. PubMed ID: 783214
    [No Abstract]   [Full Text] [Related]  

  • 44. Protein binding and kinetics of drugs in liver diseases.
    Blaschke TF
    Clin Pharmacokinet; 1977; 2(1):32-44. PubMed ID: 322909
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Liver disease and drug therapy.
    Black M
    Med Clin North Am; 1974 Sep; 58(5):1051-7. PubMed ID: 4608944
    [No Abstract]   [Full Text] [Related]  

  • 46. Hepatic clearance measurements and pharmacokinetics.
    Keiding S; Andreasen PB
    Pharmacology; 1979; 19(3):105-10. PubMed ID: 392549
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prescribing in patients with abnormal liver function tests.
    Smith E; Desmond P
    Aust Fam Physician; 2013; 42(1-2):30-3. PubMed ID: 23529456
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Drug metabolism and liver disease in India.
    Narang AP; Kaur U; Bambery P
    Drug Metab Rev; 1991; 23(1-2):65-81. PubMed ID: 1868778
    [No Abstract]   [Full Text] [Related]  

  • 49. [Dangerous drugs in hepatic insufficiency].
    Isal JP; Caulin C
    Med Chir Dig; 1979; 8(5):447-9. PubMed ID: 534025
    [No Abstract]   [Full Text] [Related]  

  • 50. Pharmacokinetics in liver disease.
    Breimer DD
    Pharm Weekbl Sci; 1987 Apr; 9(2):79-84. PubMed ID: 3295764
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The application of clearance concepts to propranolol disposition in man.
    Wilkinson GR
    Drug Metab Rev; 1979; 10(1):107-23. PubMed ID: 393480
    [No Abstract]   [Full Text] [Related]  

  • 52. Critical compilation of terminal half-lives, percent excreted unchanged, and changes of half-life in renal and hepatic dysfunction for studies in humans with references.
    Pagliaro LA; Benet LZ
    J Pharmacokinet Biopharm; 1975 Oct; 3(5):333-83. PubMed ID: 1107513
    [No Abstract]   [Full Text] [Related]  

  • 53. [Clinical significance of disorders of drug kinetics in liver diseases].
    Bolanowski M; Orzechowska-Juzwenko K
    Pol Arch Med Wewn; 1986 Apr; 75(4):288-96. PubMed ID: 3540881
    [No Abstract]   [Full Text] [Related]  

  • 54. Hepatic first-pass metabolism in liver disease.
    Blaschke TF; Rubin PC
    Clin Pharmacokinet; 1979; 4(6):423-32. PubMed ID: 391462
    [No Abstract]   [Full Text] [Related]  

  • 55. Single-point prediction methods: a critical review.
    Koup JR
    Drug Intell Clin Pharm; 1982 Nov; 16(11):855-62. PubMed ID: 7173047
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Some clinical features of liver cell failure: an appraisal of their causes.
    Read AE
    Gut; 1978 Jun; 19(6):543-8. PubMed ID: 355067
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Serum creatinine and drug half-lives.
    Kampmann J; Hansen JM; Siersbaek-Nielsen K; Kristensen M
    JAMA; 1973 Jan; 223(2):193. PubMed ID: 4739466
    [No Abstract]   [Full Text] [Related]  

  • 58. Accumulation and time to steady state for drugs subject to enterohepatic cycling: a stimulation study.
    Shepard TA; Gannaway DJ; Lockwood GF
    J Pharm Sci; 1985 Dec; 74(12):1331-3. PubMed ID: 4087202
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Genetic and environmental factors affecting drug disposition in man.
    Vesell ES
    Clin Pharmacol Ther; 1977 Nov; 22(5 Pt 2):659-79. PubMed ID: 334437
    [No Abstract]   [Full Text] [Related]  

  • 60. [The risk of drug overdosage in hepatic diseases].
    Bircher J
    Acta Gastroenterol Belg; 1988; 51(1):102-5. PubMed ID: 3188815
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.